Search...
/
The Fly Cast
Press play to listen
Competitive Advantages
Risks
Competitive Advantages
Novel Mechanism of Action: Inhibikase's lead candidate, IKT-148009, targets the c-Abl kinase pathway, representing a novel approach for neurodegenerative diseases like Parkinson's, aiming to halt or reverse disease progression rather than merely managing symptoms.
Clinical-Stage Lead Program: With IKT-148009 in clinical trials for Parkinson's disease, the company has de-risked its platform and is progressing towards potential market entry, demonstrating human proof-of-concept.
Robust Intellectual Property: Inhibikase owns a comprehensive portfolio of patents covering its c-Abl kinase inhibitors and their applications across various neurodegenerative indications, providing exclusivity and competitive barriers.
Risks
Clinical Trial Outcomes: Our drug candidates may fail to demonstrate safety or efficacy in clinical trials, leading to significant delays or discontinuation of development.
Regulatory Approval Uncertainty: We may not receive the necessary regulatory approvals from bodies like the FDA or EMA for our drug candidates, preventing us from marketing them.
Funding and Cash Burn: We have a history of net losses and will require significant additional funding to continue our research and development, which may not be available on favorable terms or at all.
Today
5:01 PM
Over a week ago
Jun 10, 7:32 AM
Apr 7, 8:18 AM
Mar 4, 7:38 AM
Mar 4, 6:47 AM
Jan 21, 6:27 AM
Dec 26, 6:06 AM
Dec 11, 7:57 AM
Nov 20, 10:55 PM
Nov 20, 4:48 PM
Nov 20, 4:14 PM
Nov 20, 4:05 PM
Aug 19, 8:11 AM
No more stories
